×

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson’s and Movement Disorders

EMERYVILLE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company’s Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease, will be highlighted in two poster presentations at the 20th Annual International Congress of Parkinson’s and Movement Disorders, being held June 19 to 23, 2016, in Berlin, Germany.

The two poster presentations are as follows:

  • Interim Results of a Long-term Open-label Safety Study of ADS-5102 (amantadine HCl) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)
    • Abstract Number: LBA 07
    • Presentation Date: Wednesday, June 22, 2016
    • Session time: 12:00 – 13:30 CET
    • Location: Exhibit Hall located in Hall B, Level 2
  • ADS-5102 (amantadine HCl) Extended-Release Capsules Reduced Levodopa-Induced Dyskinesia in the Phase 3 EASE LID Study
    • Abstract number: 2012
    • Guided poster topic tour: Pharmacology
    • Presentation Date: June 23, 2016
    • Presentation time: 12:00 – 13:30 CET
    • Location: Exhibit Hall located in Hall B, Level 2

Additional information about the conference can be found on the conference website: http://www.mdscongress2016.org/Congress-2016.htm. Abstracts are expected to be available on-line on Saturday, June 18.

ADS-5102 Phase 3 Program Overview
Adamas’ Phase 3 clinical program of ADS-5102 for the treatment of LID comprises three placebo-controlled trials: EASED, EASE LID and EASE LID 3. These trials enrolled a total of 286 patients, of which 122 patients received a 340 mg dose of ADS-5102 once daily before bedtime for a prespecified period of time. In all three trials, changes in LID versus placebo were assessed by the UDysRS: week 8 (EASED), week 12 and week 24 (EASE LID) and week 12 (EASE LID 3). EASE LID 2, an open-label safety study, is open to patients from EASED, EASE LID and EASE LID 3 and to LID patients who have undergone deep brain stimulation, is ongoing.

About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy. In addition, under a license agreement with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc., the company is eligible to receive royalties from Forest on sales of Namenda XR® and Namzaric™ beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

For questions, please contact: Julie Wood Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3528

Source:Adamas Pharmaceuticals, Inc.